DOI: 10.1007/s00259-018-4207-9Pages: 1-18

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

1. University of Copenhagen, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet

2. Ludwig-Maximilians-University, Department of Nuclear Medicine

3. University of Navarre, Department of Nuclear Medicine, Clínica Universidad de Navarra

4. University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging

5. VU University Medical Center, Department of Radiology and Nuclear Medicine

6. University Hospital Cologne, Department of Nuclear Medicine

7. University Hospital Cologne, Department of Neurology

8. Forschungszentrum Julich, Institute of Neuroscience and Medicine (INM-3, -4)

9. University of Tübingen, Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology

10. RWTH University Aachen, Department of Nuclear Medicine

11. Humanitas Clinical and Research Hospital, Department of Nuclear Medicine

12. Mayo Clinic, Department of Radiology, Nuclear Medicine

13. University of Alabama at Birmingham, Division of Molecular Imaging and Therapeutics

14. University Hospital Essen, High-Field and Hybrid MR Imaging

15. University Hospital Leipzig, Department for Nuclear Medicine

16. Emory University, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences

17. Ludwig-Maximilians-University Munich, Department of Neurosurgery

18. University Hospital Zurich, Department of Neurology

Correspondence to:
Ian Law
Tel: +45 35 45 85 13



These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374–80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199–208, 2016). The information provided should be taken in the context of local conditions and regulations.

This article is freely available, click here to access the full text/PDF

  • Accepted: Oct 29, 2018
  • Online: Dec 5, 2018

Article Tools